← Back to Screener
Pyxis Oncology, Inc. Common Stock (PYXS)
Price$1.70
Favorite Metrics
Price vs S&P 500 (26W)-63.88%
Price vs S&P 500 (4W)3.43%
Market Capitalization$104.30M
All Metrics
Book Value / Share (Quarterly)$0.85
P/TBV (Annual)1.34x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.01
Price vs S&P 500 (YTD)40.21%
EPS (TTM)$-0.93
10-Day Avg Trading Volume0.41M
EPS Excl Extra (TTM)$-0.93
EPS (Annual)$-1.28
ROI (Annual)-149.02%
Gross Margin (Annual)82.77%
Cash / Share (Quarterly)$1.07
ROA (Last FY)-87.00%
Revenue Growth TTM (YoY)-14.17%
EBITD / Share (TTM)$-0.85
ROE (5Y Avg)-75.19%
Cash Flow / Share (Annual)$-1.01
P/B Ratio1.95x
P/B Ratio (Quarterly)1.34x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-10.80x
ROA (TTM)-49.30%
EPS Incl Extra (Annual)$-1.28
Current Ratio (Annual)3.41x
Quick Ratio (Quarterly)3.23x
3-Month Avg Trading Volume0.90M
52-Week Price Return77.75%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.85
P/S Ratio (Annual)7.53x
Asset Turnover (Annual)0.15x
52-Week High$5.55
EPS Excl Extra (Annual)$-1.28
CapEx CAGR (5Y)-63.96%
26-Week Price Return-55.14%
Quick Ratio (Annual)3.26x
13-Week Price Return-16.58%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.41x
Enterprise Value$88.901
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-564.55%
Cash / Share (Annual)$1.07
3-Month Return Std Dev77.00%
Net Income / Employee (TTM)$-1
ROE (Last FY)-149.08%
Net Interest Coverage (Annual)-10.80x
EPS Basic Excl Extra (Annual)$-1.28
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.93
ROI (TTM)-70.75%
Revenue / Share (Annual)$0.22
Tangible BV / Share (Annual)$0.85
Price vs S&P 500 (52W)42.65%
Year-to-Date Return44.35%
5-Day Price Return-2.92%
EPS Normalized (Annual)$-1.28
ROA (5Y Avg)-52.58%
Net Profit Margin (Annual)-574.55%
Month-to-Date Return13.70%
Cash Flow / Share (TTM)$-2.48
EBITD / Share (Annual)$-1.24
Operating Margin (Annual)-609.18%
ROI (5Y Avg)-75.17%
EPS Basic Excl Extra (TTM)$-0.93
P/TBV (Quarterly)1.34x
P/B Ratio (Annual)1.34x
Book Value / Share (Annual)$0.85
Price vs S&P 500 (13W)-19.45%
Beta1.44x
Revenue / Share (TTM)$0.22
ROE (TTM)-70.80%
52-Week Low$0.89
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PYXSPyxis Oncology, Inc. Common Stock | — | -14.17% | — | — | $1.70 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Pyxis Oncology is a preclinical-stage company developing next-generation therapeutics targeting difficult-to-treat cancers. The company's dual approach combines direct tumor cell killing with addressing underlying cancer pathologies that enable proliferation and immune evasion. This strategy aims to improve treatment outcomes for patients with limited options.